TNF-α promotes cell cycle progression by activating NF-κB signal pathway in hepatic cell line L-02

Progress in Biochemistry and Biophysics

Volumn 34, Issue 6, 2007, Pages 604-610

  Yang, Ji Yun ^a   Zhang, Si Zhong ^a   Guo, Hong ^a   Zeng, Xiang Yuan ^b   Ma, Bu Ren ^b  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Cell cycle; Chronic inflammation; Extracellular signal regulated kinase (ERK); Nuclear factor B (NF B); Tumor necrosis factor (TNF ); Tumorigenesis

Indexed keywords

EID: 34548571965     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357 (9255): 539-545
2. Block T M, Mehta A S, Fimmel C J, et al. Molecular viral oncology of hepatocellular carcinoma. Oncogene, 2003, 22 (33): 5093 - 5107
3. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer, 2001, 84 (7): 886-891
4. Coussens L M, Werb Z. Inflammation and cancer. Nature, 2002, 420 (6917): 860-867
5. Robertson F M, Ross M S, Tober K L, et al. Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline. Carcinogenesis, 1996, 17 (8): 1719-1728
6. Moore R J, Owens D M, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 1999, 5 (7): 828-831
7. Suganuma M, Okabe S, Marino M W, et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res, 1999, 59 (18): 4516 - 4518
8. Knight B, Yeoh G C, Husk K L, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med, 2000, 192 (12): 1809-1818
9. Kollias G, Douni E, Kassiotis G, et al. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev, 1999, 169: 175-194
10. Lejeune F J, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol, 1998, 10 (5): 573-580
11. Huang C, Li J, Ma W Y, et al. JNK activation is required for JB6 cell transformation induced by tumor necrosis factor-alpha but not by 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem, 1999, 274 (42): 29672-29676
12. Jacks T, Weinberg R A. Cell-cycle control and its watchman. Nature, 1996, 381 (6584): 643-644
13. Evan G I, Vousden K H. Proliferation, cell cycle and apoptosis in cancer. Nature, 2001, 411 (6835): 342-348
14. Ioachim E, Michael M, Stavropoulos N E, et al. Expression patterns of cyclins D1, E and cyclin-depcndent kinase inhibitors p21 (Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features. Urol Int, 2004, 73 (1): 65-73
15. Herber B, Truss M, Beato M, et al. Inducible regulatory elements in the human cyclin D1 promoter. Oncogene, 1994, 9 (4): 1295-1304
16. Chung J H, Ostrowski M C, Romigh T, et al. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet, 2006, 15 (17): 2553 - 2559
17. Caron R W, Yacoub A, Mitchell C, et al. Radiation-stimulated ERK1/2 and JNK1/2 signaling can promote cell cycle progression in human colon cancer cells. Cell Cycle, 2005, 4 (3): 456-464
18. Tanaka A, Muto S, Konno M, et al. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. Cancer Res, 2006, 66 (1): 419 - 426
19. Guttridge D C, Albanese C, Reuther J Y, et al. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol, 1999, 19 (8): 5785-5799